The company, nanoDERM Sciences, Inc. (nDS), is an
early stage diagnostic and therapeutic products developer.
The company, founder and CEO, Roy Yeoman, leads the nDS R&D team which
is dedicated to the discovery, research, development, and commercialization of
innovative drug delivery, advanced wound healing, and infectious disease
therapy products. The focus of the nDS R&D
plan is to protect, expand, and develop the patented drug delivery platform for
large commercial markets of high priority medical needs.
The core technology of nDS is HydroDEX™, a new patented
copolymer molecule with broad commercial opportunity. This invention was a result of the continuing
efforts of the nDS R&D staff to develop a high capacity, Non-Toxic,
Biocompatible, Thermal-Responsive, and Biodegradable Hydrogel initially for use
as the drug delivery system in the proprietary nDS wound healing dressing. Synthesized from FDA approved Dextran and
another FDA approved polymer, HydroDEX™, should serve as a safe, universal
standard in controlled nanoparticle Drug Delivery. Combined markets in need of the nDS drug
delivery device, with tunable, “controlled-release” and “degradation” drug
delivery features are in excess of $250 Billion as defined by a Translation
Medicine Study. By invitation, and
abstract award, nDS presented its novel technology at the 2012 Drug Delivery
Partnerships Meeting, Las Vegas, NV.
Medical Unmet Needs can be solved with the HydroDEX™
drug delivery nanotechnology. The 10th
Award of the “Joint Technology Transfer Initiative” Program was won by nDS for
novel antibacterial nanomedicine to combat burn wound infections of
Drug-Resistant Bacteria. This one year
Proof of Concept R&D grant, funded by the Department of Homeland Security
supported the successful development of HydroDEX™ and in vitro testing that proves that the nDS nanotechnology successfully
“targets and safely kills DRB pathogens.“ Combating infections of Drug-Resistant
Bacteria (DRB) is a national priority as these infections add an expense of
$20-35 billion to the US healthcare system alone.
The nDS commercialization strategy is to focus,
initially, on the development of HydroDEX™ for bacterial targeting/therapy to control
DRB pathogens. Based on the need to
control infections of DRB globally, in particular within high risk patient
populations in the US military, the nDS R&D team won a 2015 Defense Health
Program (DHP) SBIR Phase I feasibility contract that delivered a working
antibacterial prototype to combat infections caused by DRB pathogens. An nDS 5 year DHP contract has successfully
delivered HydroDEX™ Proof of Concept Data for in vitro antibacterial activity
against multidrug resistant bacteria.
The
nDS vision is to become the market leader in the $100 billion Infectious
Disease Market and license it’s IP to the rapidly growing Targeted Drug
Delivery (TDD) Market. Our focus is to
produce antibacterial nanomedicine to combat Burn Wound Sepsis, the most common
and serious complication of major burn injury, accounting for over 60% of
deaths in burn patients today. Sepsis
(which affects about 750,000 US patients each year, killing one person every
2.5 minutes) is mostly caused by “bacterial infections” which can be treated
with our patented therapy. High profits are assured for the nDS investor
supporting company efforts to fulfill this high priority unmet therapeutic need. The company ownership seeks partners to accelerate
the commercialization of our patented therapy to combat multidrug resistant pathogens,
bacteremia, and treat sepsis victims.
For
the nDS. Inc. business plan and
financials contact:
Roy Yeoman at ryeoman@nanodermsciences.com, phone: 703-994-5856.
